Firmonertinib (previously referred to as alflutinib and furmonertinib) is targeted drug that that is approved in China for the treatment of non-small cell lung cancer (NSCLC). The originator of the drug was Shanghai Allist Pharmaceuticals. It is now being developed outside China through a licensing deal with ArriVent BioPharma, Inc. for the same indication. It is a epidermal growth factor receptor (EGFR) antagonist.
Pharmacology Firmonertinib is an EGFR inhibitor that binds irreversibly through a chemical reactive acrylamide to the Cys-797 residue of the ATP-binding site of EGFR via a Michael addition to form a covalent bond. It has binding selectivity for T790M mutant over wild‑type EGFR.
Clinical trials Firmonertinib is currently in phase 3 clinical trials in North America, Europe, and Asia for non-small cell lung cancer in the.
Approvals It was approved for use in China in 2021 in NSCLC patients with confirmed EGFR T790M mutations.
References